Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Bcl-xL inhibition radiosensitizes PIK3CA/PTEN wild-type triple negative breast cancers with low Mcl-1 expression.
Pesch AM, Chandler BC, Michmerhuizen AR, Carter HM, Hirsh NH, Wilder-Romans K, Liu M, Ward T, Ritter CL, Nino CA, Jungles KM, Pierce LJ, Rae JM, Speers CW. Pesch AM, et al. Among authors: michmerhuizen ar. Cancer Res Commun. 2022 Jul;2(7):679-693. doi: 10.1158/2767-9764.crc-22-0024. Epub 2022 Jul 20. Cancer Res Commun. 2022. PMID: 36381235 Free PMC article.
Publisher Correction: Estrogen receptor inhibition mediates radiosensitization of ER-positive breast cancer models.
Michmerhuizen AR, Lerner LM, Pesch AM, Ward C, Schwartz R, Wilder-Romans K, Liu M, Nino C, Jungles K, Azaria R, Jelley A, Zambrana Garcia N, Harold A, Zhang A, Wharram B, Hayes DF, Rae JM, Pierce LJ, Speers CW. Michmerhuizen AR, et al. NPJ Breast Cancer. 2022 Apr 20;8(1):54. doi: 10.1038/s41523-022-00418-w. NPJ Breast Cancer. 2022. PMID: 35444242 Free PMC article. No abstract available.
Estrogen receptor inhibition mediates radiosensitization of ER-positive breast cancer models.
Michmerhuizen AR, Lerner LM, Pesch AM, Ward C, Schwartz R, Wilder-Romans K, Liu M, Nino C, Jungles K, Azaria R, Jelley A, Zambrana Garcia N, Harold A, Zhang A, Wharram B, Hayes DF, Rae JM, Pierce LJ, Speers CW. Michmerhuizen AR, et al. NPJ Breast Cancer. 2022 Mar 10;8(1):31. doi: 10.1038/s41523-022-00397-y. NPJ Breast Cancer. 2022. PMID: 35273179 Free PMC article.
Short-term CDK4/6 Inhibition Radiosensitizes Estrogen Receptor-Positive Breast Cancers.
Pesch AM, Hirsh NH, Chandler BC, Michmerhuizen AR, Ritter CL, Androsiglio MP, Wilder-Romans K, Liu M, Gersch CL, Larios JM, Pierce LJ, Rae JM, Speers CW. Pesch AM, et al. Among authors: michmerhuizen ar. Clin Cancer Res. 2020 Dec 15;26(24):6568-6580. doi: 10.1158/1078-0432.CCR-20-2269. Epub 2020 Sep 23. Clin Cancer Res. 2020. PMID: 32967938 Free PMC article.
Seviteronel, a Novel CYP17 Lyase Inhibitor and Androgen Receptor Antagonist, Radiosensitizes AR-Positive Triple Negative Breast Cancer Cells.
Michmerhuizen AR, Chandler B, Olsen E, Wilder-Romans K, Moubadder L, Liu M, Pesch AM, Zhang A, Ritter C, Ward ST, Santola A, Nyati S, Rae JM, Hayes D, Feng FY, Spratt D, Wahl D, Eisner J, Pierce LJ, Speers C. Michmerhuizen AR, et al. Front Endocrinol (Lausanne). 2020 Feb 11;11:35. doi: 10.3389/fendo.2020.00035. eCollection 2020. Front Endocrinol (Lausanne). 2020. PMID: 32117061 Free PMC article.
TTK inhibition radiosensitizes basal-like breast cancer through impaired homologous recombination.
Chandler BC, Moubadder L, Ritter CL, Liu M, Cameron M, Wilder-Romans K, Zhang A, Pesch AM, Michmerhuizen AR, Hirsh N, Androsiglio M, Ward T, Olsen E, Niknafs YS, Merajver S, Thomas DG, Brown PH, Lawrence TS, Nyati S, Pierce LJ, Chinnaiyan A, Speers C. Chandler BC, et al. Among authors: michmerhuizen ar. J Clin Invest. 2020 Feb 3;130(2):958-973. doi: 10.1172/JCI130435. J Clin Invest. 2020. PMID: 31961339 Free PMC article.
11 results